Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11705279 | 0.85 | TSHR (0.45) | CA1CA2CA9ERN1ALDH1A1 | |
| SCHEMBL12040568 | 0.85 | CA1 (0.42) | CA1CA2CA9ERN1ALDH1A1 | |
| SCHEMBL11024448 | 0.82 | ERN1 (0.46) | CA1CA2CA9ERN1ALDH1A1 | |
| SCHEMBL11700000 | 0.80 | AKR1C4 (0.39) | CA1CA2CA9ERN1ALDH1A1 | |
| SCHEMBL11705802 | 0.80 | AKR1C4 (0.52) | CA1CA2ALDH1A1TSHRHSD17B10 | |
| SCHEMBL16546180 | 0.76 | ERN1 (0.32) | ERN1TSHR | |
| SCHEMBL1764467 | 0.75 | CA1 (0.40) | CA1CA2CA9ERN1ALDH1A1 | |
| SCHEMBL3390853 | 0.75 | CA1 (0.40) | CA1CA2CA9ERN1ALDH1A1 | |
| SCHEMBL8667994 | 0.75 | ALDH1A1 (0.48) | ALDH1A1TDP1TSHRCYP1A2KMT2A | |
| SCHEMBL11783352 | 0.75 | CA1 (0.41) | CA1CA2CA9ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119930708-A | Preparation method of (3, 3-dimethyl-1-butyne) hexacarbonyl cobalt | 上海庆建廷科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| US-12091395-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-17 | — | — | US | claimed |
| US-20240150309-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| EP-3109251-B1 | METHOD FOR PRODUCING INHIBITOR OF ACTIVATED BLOOD COAGULATION FACTOR X (FXA) | DAIICHI SANKYO CO LTD (JP) | 2020-07-15 | — | — | EP | claimed |
| US-20170050983-A1 | METHOD FOR PRODUCING INHIBITOR OF ACTIVATED BLOOD COAGULATION FACTOR X (FXA) | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-23 | — | — | US | claimed |
| EP-3109251-A1 | METHOD FOR PRODUCING INHIBITOR OF ACTIVATED BLOOD COAGULATION FACTOR X (FXA) | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-12-28 | — | — | EP | claimed |
| WO-2026107422-A1 | 6-(PYRIDIN-4-YL)-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026107424-A1 | N-(4-(IMIDAZO[4,5-B]PYRIDIN-5-YL)-2-PYRIDYL)BENZAMIDE DERIVATIVES AS CAMK2 INHIBITORS FOR THE TREATMENT OF HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12577217-B2 | 15-PGDH inhibitor | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| US-12492187-B2 | Factor XI activation inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
| US-4259350-A | PROTECTING DEGRADABLE ORGANIC MATERIAL FROM FUNGAL OR INSECT ATTACK | SANKYO COMPANY LIMITED (JP) | 1981-03-31 | — | — | US | disclosed |
| US-4059565-A | Process for producing a branched polycarbonate or poly(ester-carbonate) | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JA) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577217-B2 | 15-PGDH inhibitor | PTGDR, ADH1A, ADRA1A | CA1 1410/4885CA2 1125/4885CA9 1273/4885 |
| US-12492187-B2 | Factor XI activation inhibitors | F11, TFPI, F13B | CA1 2074/4885CA2 1634/4885CA9 378/4885 |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | CA1 4062/4885CA2 4790/4885CA9 4651/4885 |
| US-20240150309-A1 | GRISEOFULVIN COMPOUND | PTGS1, CYP11B1, GRIA1 | CA1 2530/4885CA2 1188/4885CA9 2914/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | CA1 1098/4885CA2 258/4885CA9 1476/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | CA1 4656/4885CA2 4713/4885CA9 4828/4885 |
| US-20170050983-A1 | METHOD FOR PRODUCING INHIBITOR OF ACTIVATED BLOOD COAGULATION FACTOR X (FXA) | F12, F11, F2 | CA1 307/4885CA2 308/4885CA9 480/4885 |
| US-12091395-B2 | Griseofulvin compound | PTGS1, CYP11B1, GRIA1 | CA1 2530/4885CA2 1188/4885CA9 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.